U.S., May 10 -- ClinicalTrials.gov registry received information related to the study (NCT06964009) titled 'DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer' on April 08.
Brief Summary: The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer.
The names of the study drugs involved in this study are:
* DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein)
* Paclitaxel (a type of antimicrotubule agent)
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Ovarian Cancer
Ovarian Carcinoma
Recurrent Ovary Cancer
Recurrent Platinum-Resistant Ovarian Carcinom...